Attovia Therapeutics Inc. (ATTO:NASDAQ) closed at $13.88 on October 26, 2026, up 0.36% on the day. The stock trades 50.4% below its 52-week high of $28.00 and 7.3% above its 52-week low of $12.94. Over the past year, it lost 36.8%. Attovia Therapeutics Inc. is part of the Health Care sector.
In 57 trading sessions since August 6, 2026, ATTO closed higher on 25 days (44%). Its best day was August 17, 2026 (+14.35%) and its worst was September 23, 2026 (-11.09%). The stock moved 10% or more in a single session 2 times.
Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using our ATTOBODY biparatopic biologics platform. Attovia's ATTOBODY platform uses an evolution-driven, high-throughput process which allows for rapid discovery and creation of a high diversity of potential product candidates. Attovia's lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases, ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases, and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin ¿4¿7 in IND-enabling studies for inflammatory bowel disease. Attovia's other programs include highly innovative conditional 'AND' gated bispecific immune cell survival blockers and multispecifics.
Find more stocks like ATTO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.